Results 121 to 130 of about 390,906 (164)

Ethnomedicinal Uses, Phytochemistry, Pharmacological Activities, and Toxicology of the Subfamily Gomphrenoideae (Amaranthaceae): A Comprehensive Review

Chemistry &Biodiversity, EarlyView.
ABSTRACT The subfamily Gomphrenoideae is composed of about 480 accepted species, many of which have been historically used as medicinal plants, reason why they have been studied in terms of chemical profile, biological activity, and safety. This review consolidates the advances in research on this subfamily over the past 47 years, emphasizing its ...
Dayanna Isabel Araque Gelves, Giulia Cristina de Andreoli Souza, Alvaro Jose Hernandez Tasco, Marcos José Salvador   +3 more
wiley   +1 more source

Older adults living with gastrointestinal cancers in 2021

Cancer Communications, EarlyView.
Pojsakorn Danpanichkul, Yanfang Pang, Torlap Inkongngam, Kornnatthanai Namsathimaphorn, Krittameth Rakwong, Chuthathip Kaeosri, Benjamin Nah, Kwanjit Duangsonk, Nicole Shu Ying Tang, Neha Mittal, Donghee Kim, Mazen Noureddin, Michael B. Wallace, Amit G. Singal, Karn Wijarnpreecha, Ju Dong Yang   +15 more
wiley   +1 more source

Selective [9‐15N] Guanosine for Nuclear Magnetic Resonance Studies of Large Ribonucleic Acids

ChemBioChem, EarlyView.
The small chemical shift anisotropy of nitrogen‐15 at the 9‐position in guanine (15N9‐G) leads to long T2 values and narrow NMR lines, particularly attractive to probe structure and dynamics of large (>200 nucleotide) ribonucleic acids (RNAs). RNAs regulate various cellular processes using malleable 3D structures, and understanding the factors that ...
Solomon K. Attionu, Rita Dill, Michael F. Summers, David A. Case, Jan Marchant, Theodore K. Dayie   +5 more
wiley   +1 more source

Development and Recent Advances in SLIPT‐PM: A Chemogenetic Platform for Manipulating Signaling at the Plasma Membrane

ChemBioChem, Accepted Article.
Upon cell stimulation, mammalian cells activate various signaling proteins and lipids by recruiting their upstream regulators to the inner leaflet of the plasma membrane (PM), which in turn determines their cellular response. Therefore, artificially inducing protein translocation to the PM is an effective strategy for dissecting cell signaling networks
Shuya Ohira, Akinobu Nakamura, Kenta Terai, Shinya Tsukiji   +3 more
wiley   +1 more source

Landelijke Richtlijn Preventie iatrogene Hepatitis B [PDF]

, 2007
Commissie Preventie Transmissie Iatrogene Hepatitis B
core  

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Advances in Isotope Labeling for Solution Nucleic Acid Nuclear Magnetic Resonance Spectroscopy

ChemPlusChem, EarlyView.
Recent advances in the field of nucleic acid nuclear magnetic resonance (NMR) are presented. Stable isotope labeling protocols and new approaches to segmentally label nucleic acid with NMR‐active residues are summarized. The novel methods will have a strong impact on the future of nucleic acid NMR and the characterization of structure and dynamics of ...
Stefan Hilber, Solomon Kojo Attionu, Theodore Kwaku Dayie, Christoph Kreutz   +3 more
wiley   +1 more source